[1] |
CHEN Zhenmei, CHEN Jinhong.
Advances in precision diagnosis and treatment of cholangiocarcinoma
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(2): 159-170.
|
[2] |
LIU Jing, LEI Guojie, CAO Jinghao, YU Lingyan, DU Jing, WANG Ying.
Mechanism of doxorubicin/copper complex induced cuproptosis in hepatocellular carcinoma cells
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(1): 1-10.
|
[3] |
LEI Guojie, YU Yanhua, LIU Yingchao, BIAN Wenxia, DU Jing, TONG Xiangmin.
Mechanism of PX-12 induced apoptosis of hepatocellular carcinoma cells through oxidative stress
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(9): 961-967.
|
[4] |
LAN Xueling, HUANG Yanni, ZHU Minmin, MA Ping, DONG Min.
Advances of VEGF signalling pathway in hepatocellular carcinomar invasion and metastasis and therapy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(6): 707-714.
|
[5] |
WANG Linlin, MA Yuan, CHEN Zhihong, JI Haiying .
Progress in the application of AIT in allergic airway diseases
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(4): 427-431.
|
[6] |
ZHANG Zhipeng, CHEN Ziqi, TIAN Jianhui.
The attenuating and potentiating effects of traditional Chinese medicine in immune checkpoint therapy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(3): 339-347.
|
[7] |
HE Lihua, ZHU Xiuzhi, JIANG Yizhou.
Research progress on immunotherapy for triple-negative breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 842-853.
|
[8] |
HOU Qiong, LIU Fei, CHEN Chuanrong.
Immunotherapy combined with anti-angiogenic drugs and chemotherapy in negative driver gene and advanced non-small cell lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 775-779.
|
[9] |
QIAO Hongliang, DING Ning, DENG Kaihong, LIU Binbin, DONG Chuanjiang, CHEN Xiaobo, ZOU Lili.
New progress in research on novel control strategies for methicillin-resistant staphylococcus aureus infection
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 676-687.
|
[10] |
WANG Dan, YAN Xiaoli, ZHANG Yuan.
Helicobacter pylori infection influences the efficacy of immunotherapies for gastric cancer#br#
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 228-234.
|
[11] |
WU Xianchuang, LIU Yuxin, NIU Yuji, HE Jinjin, QIAO Hui, ZHANG Leilei.
Mechanism of DCLK1 transcriptional regulation in HCC
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1241-1246.
|
[12] |
LI Wei, HU Jiali, WANG Kai, HE Yijing.
Research progress and prospect of immunotherapy in the treatment of melanoma
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1053-1064.
|
[13] |
YE Kaili, ZHENG Wen, YE Qifa, YANG Lan .
Mechanism of CDK1 participates in the development of hepatocellular carcinoma and its inhibitor application value
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1086-1094.
|
[14] |
YU Saihong, ZHENG Xiaoliang, PU Yiyi, YAN Dongmei, WANG Xiaoju, YU Jie.
Reversal of 5-fluorouracil resistance in hepatocellular carcinoma cells by inhibiting ribonucleotide reductase M2
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 729-737.
|
[15] |
SONG Ruzheng, PENG Ying, WANG Guangji, SUN Jianguo.
Commonly used quantitative proteomics research techniques and their application in the study of pathogenesis of liver-derived diseases
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 570-578.
|